^
    Back
    Association details:
    Biomarker:S100A9 expression
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor) +
    Farydak (panobinostat) (HDAC inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    EHA 2020
    Title:

    THE ASSOCIATION OF CALCIUM BINDING PROTEINS S100A8 AND S100A9 WITH DRUG RESPONSE IN MULTIPLE MYELOMA

    Published date:
    05/14/2020
    Excerpt:
    Significant correlation was observed between expression of S100A8/S100A9 and resistance to bortezomib and panobinostat . These preliminary data indicate S100A8 and S100A9 may play a critical role in the development of resistance to these drugs in MM patients .